Exploring Food Preferences in Cancer Patients on the Mediterranean Diet
Evaluation of Changes in Adherence to the Mediterranean Diet in Cancer Patients Undergoing Treatment
This study looks at how cancer patients stick to the Mediterranean diet during treatment and how changes in their taste and smell might affect their food choices.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 442 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Centre Antoine Lacassagne Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Nice) |
| Trial ID | NCT06058312 on ClinicalTrials.gov |
What this trial studies
This exploratory study aims to understand how cancer patients adhere to the Mediterranean diet during treatment, focusing on sensory changes that may affect their dietary choices. It employs a multidisciplinary approach, examining various factors influencing dietary behavior, including sensory perception and psychological aspects. Patients will complete self-questionnaires to assess their taste and smell responses to different foods and aromas associated with the Mediterranean diet. The study seeks to enrich scientific knowledge about the dietary habits of cancer patients undergoing chemotherapy or immunotherapy.
Who should consider this trial
Good fit: Ideal candidates are cancer patients aged 18-70 who are starting chemotherapy or immunotherapy and can return for follow-up assessments.
Not a fit: Patients unable to eat or those with specific dietary restrictions due to medical conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved dietary recommendations for cancer patients, enhancing their treatment experience and overall well-being.
How similar studies have performed: While there is existing literature on dietary interventions in cancer care, this specific approach focusing on individual food preferences within the Mediterranean diet is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient aged 18-70 years old, * Patient cared for at the Center Antoine Lacassagne (CAL) Day Hospital and needing to start chemotherapy or immunotherapy, * Patient to return to the Antoine Lacassagne center in their 9th week of therapy, * Patient who has not received chemotherapy or specific treatment in the 3 months prior to inclusion (wash-out period of 3 months), * Patient having read the information note and having attested to his non-objection * Patient not having objected to the use of this data in the context of medical research * Patient affiliated with a Social Security scheme. Exclusion Criteria: * Inability to eat, or patient with enteral/parenteral nutrition, * Patient who has undergone gastric surgery, * Patient undergoing radiotherapy at the level of the ENT sphere (due to the possibility of affection of the mouth due to the RTH), * Patient with cancer of the ENT sphere (upper aerodigestive tract), * Patient with an allergy or intolerance to one of the foods offered during the sensory test sessions * Vulnerable persons as defined in article L1121-5 to -8: * Pregnant women, parturients and breastfeeding mothers, * Persons deprived of their liberty by a judicial or administrative decision, persons hospitalized without consent under Articles L. 3212-1 and L. 3213-1 who do not fall under the provisions of Article L. 1121-8, * and persons admitted to a health or social establishment for purposes other than research, * Adults subject to a legal protection measure or unable to express their consent.
Where this trial is running
Nice
- Centre Antoine lacassagne — Nice, France (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.